Search
Crisaborole
go.drugbank.com/drugs/DB05219ApprovedInvestigationalIt is currently under development as topical treatment of psoriasis. … Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis.
LU-31130
go.drugbank.com/drugs/DB05828ExperimentalLU-31130 is a rapid acting therapy developed by H. Lundbeck A/S to treat Psychosis, Schizophrenia and Schizoaffective Disorders.
Amylocaine
go.drugbank.com/drugs/DB09088ApprovedWithdrawn, and prilocaine in the 1940s and 1950s superseded and made the use of amylocaine obsolete. … Elsewhere in English speaking countries it was referred to as Stovaine, given the meaning of the French word 'fourneau' as 'stove' in English [L1882].
Seproxetine
go.drugbank.com/drugs/DB06731ExperimentalSeproxetine is also known as (S)-norfluoxetine. It is a selective serotonin reuptake inhibitor (SSRI). It is an active metabolite of fluoxetine. … Seproxetine was being investigated by Eli Lilly as an antidepressant but development was never completed and the drug was never marketed.
Synonyms: (S)-norfluoxetineSuccinobucol
go.drugbank.com/drugs/DB05399InvestigationalAGI-1067, is a novel small molecule with anti-oxidant and anti-inflammatory properties that was discovered by AtheroGenics and designed to treat atherosclerosis of the blood vessels of the heart, or coronary
Bunamiodyl
go.drugbank.com/drugs/DB04814ApprovedWithdrawnWithdrawn from the Canadian, US, and UK markets in 1963 due to nephropathy.
Dantron
go.drugbank.com/drugs/DB04816ApprovedWithdrawnWithdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.
Oxeladin
go.drugbank.com/drugs/DB04822ApprovedWithdrawnWithdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.
Algestone acetophenide
go.drugbank.com/drugs/DB15775InvestigationalCategories: Hormonal Contraceptives for Systemic UseCefilavancin
go.drugbank.com/drugs/DB05735InvestigationalCefilavancin is a covalently-linked glycopeptide-cephalosporin (beta-lactam) heterodimer antibiotic that exhibits substantially greater activity than its component parts against Gram-positive bacteria.